Skip to main content

EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits.

Bencze E, Bogos K, Kohánka A, Báthory-Fülöp L, Sárosi V, Csernák E, Bittner N, Melegh Z, Tóth E

Publication: Pathol Oncol Res (2022) • Vol 28 • Page 1610607PMID: 36277960View on PubMed

Purpose

This paper compared the accuracy of two different real-time PCR-based platforms on detecting EGFR mutations in plasma specimens from patients diagnosed with non-small cell lung cancer (NSCLC).  The capability of the AmoyDx Super-ARMS EGFR Mutation Detection Kit to detect mutations in plasma was evaluated by comparing results to those obtained in a small number of non-plasma (resection, biopsy, pleural effusions, cell blocks, and cytology smear) specimens. Effects associated with the number of specimens used and DNA concentration on detection of the EGFR T790M mutation was also investigated.

Conclusion

When analyzed using the AmoyDx Super-ARMS EGFR Mutation Detection Kit (AmoyDx Kit), 17 plasma specimens and one resection specimen returned invalid results. The same mutation detected in the primary tumor was detected in 181 of the 397 plasma specimens evaluated (45.6%) using the AmoyDx Kit. The T790M EGFR mutation was detected in 50 of 87 cases with a known mutation in a matched tumor specimen when a single blood specimen was used with the AmoyDx Kit, in 82 cases when two blood specimens were analyzed, in 86 cases when three specimens were used, and in all 87 when four blood specimens were analyzed.  The T790M EGFR mutation was detected using the AmoyDx Kit in 70.3% of patients when non-plasma specimens were used but only in 29.8% of cases when plasma specimens alone were used (P<0.0001). Importantly, the detection of T790M in plasma by the AmoyDx Kit increased to 42.4% in specimens in which the primary mutation was detected in plasma.  Detection of the T790M mutation using the AmoyDx Kit was not correlated with DNA concentration. Using plasma concordant results were obtained using the Cobas EGFR Mutation Test v2 (Cobas Kit) and the AmoyDx Kit in 85% of cases, with 89% concordance for detection of the EGFR activating mutation and 93% concordance for detection of the T790M mutation. However, T790M mutations were detected in more plasma specimens using the AmoyDx Kit than the Cobas Kit. Further, the rate of concordance of plasma and tissue EGFR mutation results was slightly, but not significantly, better when plasma was analyzed with the AmoyDx Kit than the Cobas test.

Studies (1)

Purpose

This study compared the accuracy of two different real-time PCR-based platforms on detecting EGFR mutations in plasma specimens from patients diagnosed with non-small cell lung cancer (NSCLC).  The capability of the AmoyDx Super-ARMS EGFR Mutation Detection Kit to detect mutations in plasma was evaluated by comparing results to those obtained in a small number of non-plasma (resection, biopsy, pleural effusions, cell blocks, and cytology smear) specimens. Effects associated with the number of specimens used and DNA concentration on detection of the EGFR T790M mutation was also investigated. A total of 364 blood specimens (1 to 6 per patient), 3 pleural effusions, 5 cell blocks, 6 cytology smears, 6 lung resection specimens and 17 lung biopsies were collected from 242 patients with non-small cell lung cancer (NSCLC), many of which had a known EGFR mutation and were previously treated with tyrosine kinase inhibitors. Depending on logistical requirements, blood and pleural effusions were collected in K2EDTA S-Monovette tubes and stored at 4°C for <2 h or collected in Cell-Free DNA BCT Streck tubes and stored at room temperature for < 72 h, depending on required transportation. No details for collection and processing of cell block, cytology smears or biopsies were provided. Plasma was separated from blood by centrifugation at 3000 × g for 10 min followed by 12,000 × g for 10 min and used immediately for extraction or stored for <3 days at -80°C. Cells were removed from pleural effusions by centrifugation at 1700 x g for 10 min. cfDNA was extracted from plasma and pleural effusion supernatant using the Cobas ctDNA Sample Preparation Kit. Cell blocks, cytology smears, resection specimens, and biopsies from lung were deparaffinized and lysed with reagents from the Maxwell RSC DNA FFPE Kit before cfDNA extraction with the ReliaPrep DNA Clean-Up and Concentration System Kit. Isolated cfDNA was quantified using the Qubit1X dsDNA HS Assay Kit and stored at 4°C. EGFR mutations were detected in 86 specimens (of which 73 were plasma) using the Cobas EGFR Mutation Test v2 on a Cobas z480 Analyzer and in all specimens using the AmoyDx EGFR Mutation Detection Kit with a LightCycler 480 II instrument.

Summary of Findings

Excessive hemolysis precluded the analysis of four plasma specimens. When analyzed using the AmoyDx EGFR Mutation Detection Kit, 17 plasma specimens and one lung resection specimen returned invalid results. The same mutation found in the primary tumor was detected in 181 of the 397 total specimens (45.6%) evaluated using the AmoyDx Kit. The T790M EGFR mutation was detected using the AmoyDx Kit in 50 of 87 cases when a single blood specimen was analyzed, in 82 cases when two blood specimens were analyzed, in 86 cases when three blood specimens were used, and in all 87 cases when four blood specimens were analyzed.  The EGFR T790M mjutation was detected in 70.3% of patients using the AmoyDx Kit when non-plasma specimens were used but was detected in only 29.8% of cases when plasma alone was used for analysis (P<0.0001). Importantly, the detection of the T790M mutation in plasma with the AmoyDx Kit increased to 42.4% when analysis was limited to plasma specimens that tested positive for the primary EGFR mutation., but this was still significantly lower than the 70.3% detection rate of non-plasma specimens (P=0.002444). Detection of the T790M mutation in plasma using the AmoyDx Kit was not correlated with DNA concentration. Concordant results were obtained using the Cobas and AmoyDx Kits in 85% of cases, with 89% concordance for the detection of  EGFR activating mutations and 93% concordance for detection of the T790M mutation. However, T790M mutations were detected in more specimens using the AmoyDx Kit than the Cobas Kit (23% versus 16%, P=0.014). The rate of concordance of plasma and tissue EGFR mutation results was slightly, but not significantly, higher when plasma was analyzed with the AmoyDx Kit rather than the Cobas test (88% versus 86%). The rate of concordance of plasma and tissue results for each EGFR mutation type was also only slightly higher when plasma was analyzed with the AmoyDx Kit than the Cobas test (73% versus 70% for exon 19 deletions; 96% versus 94% for exon 18 mutations; 92% versus 89% for exon 21 mutations and 90% both for exon 20 mutations).

 

  • Biospecimens

    FluidBlood
    TissueLung
    FluidPlasma
    FluidPleural Fluid
  • Preservation Types

    FormalinFrozen
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    DNAReal-time qPCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen Aliquots and ComponentsBiospecimen heterogeneity
    Multiple specimens analyzed
    Real-time qPCR SpecificDetection method
    AmoyDx Super-ARMS EGFR Mutation Detection Kit
    cobas EGFR Mutation test v2
    Real-time qPCR SpecificTemplate/input amount
    A range of concentrations